What's Next for Alnylam Pharmaceuticals, Inc.?
The past 15 years haven't been easy for Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shareholders. The company's new drug candidates are based on science that earned a Nobel Prize in 2006, but proving a clear clinical benefit that outweighs any safety concerns hasn't been nearly as easy.
This pioneering biotech took a big step forward recently with its first late-stage clinical trial victory, easing some valid concerns in the process. There are plenty of maladies caused by troublesome genes, and Alnylam has had plenty of early success targeting a handful. With surprisingly good data for its lead candidate in hand and a stable of potential new drugs in earlier development stages, we can expect a flurry of activity in the years ahead. Here are a few key developments to look for.
Alnylam shareholders have a lot to look forward to. Image source: Alnylam Pharmaceuticals, Inc.
Source: Fool.com
Alnylam Pharmace. Aktie
Die Community zeigt großes Interesse an Alnylam Pharmace. mit vielen Buy- und wenigen Sell-Einschätzungen.
Ein positives, wenn auch bescheidenes, Potenzial für Alnylam Pharmace. mit einem Kursziel von 270 € im Vergleich zum aktuellen Kurs von 226.6 €.
